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Abstract
Heart disease, dementia, and stroke are significant public health issues and leading causes
of mortality and morbidity worldwide. Abnormalities in blood perfusion and vascular structures
are seen in varieties of pathologies, including cerebrovascular diseases like stroke and dementia,
hypertension, cardiovascular disease like atherosclerosis, diabetes, peripheral artery disease, and
vasculitis, and tumor angiogenesis. Imaging perfusion/vascular abnormalities in these patients
often plays a vital role in clinical diagnosis and treatment decisions.
Vascular diseases typically present as macrovascular or microvascular diseases.
Microvascular disease (MVD) refers to vascular disease primarily affecting the arterioles,
venules, and capillaries in various organs. Furthermore, MVD is widely found in vital organs like
the brain, heart, and kidney. The assessment of MVD plays an important role in clinical
diagnosis and treatment intervention. While some imaging modalities such as echocardiography,
CT, SPECT are widely used to visualize vascular abnormalities, the ability to visualize the
microvasculature is often limited or cumbersome.

Compared with those imaging techniques,

molecular imaging has advantages in visualizing pathology processes at the molecular level to
provide early diagnosis like positron emission tomography (PET).
Nuclear blood pool imaging is widely used in the clinical setting for the evaluation of
various medical conditions, including impaired cardiac contractility, gastrointestinal hemorrhage,
and altered cerebrovascular blood flow by using radiolabeled red blood cells. Nuclear blood
perfusion imaging is commonly performed using Technetium-99m-labeled (99mTc) human
erythrocytes (i.e., the “tagged RBC” scan) and gamma camera-based planar scintigraphic
vi

imaging. However, positron emission tomography (PET) provides superior image quality and
sensitivity compared to typical clinical planar scintigraphy and single-photon emission computed
tomographic (SPECT) imaging platforms. Several PET-based radionuclide agents have been
proposed for blood pool imaging, but none have yet to be used widely in the clinical setting. In
this body of work, I describe a fast and straightforward procedure for imaging the vasculature of
the rat through a combination of a small animal positron emission tomography/computed
tomography (PET/CT) scanner and red blood cells (RBC) labeled with widely available and
inexpensive PET radiopharmaceutical tracer 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG). This
imaging approach is expected to have significant advantages over traditional

99m

Tc -labeled

erythrocyte scintigraphic nuclear imaging for a few reasons, including superior spatial resolution
and sensitivity. We first demonstrate proof of concept that the entire vascular of an
immunodeficient mouse could be visualized using FDG-labeled human red blood cells (RBC).
We showed that FDG-labeled RBC is capable of visual discrimination of the major
vessels in the mouse, such as the aorta, vena cava, and jugular veins. In addition, the
microvascularity of other organs such as the liver, lungs, and bone marrow could be visualized as
well.
In this research, we also investigate the feasibility of this method to semiquantitatively
characterize differences in the normal rat myocardial microvasculature between physiologic rest
and pharmacologic vasodilatory stress conditions. We also demonstrate the ability of
FDG-labeled RBC PET imaging to image the infarcted myocardium in a surgical myocardial
infarction rat heart model by using FDG label rat RBC and microPET/CT. Furthermore, we show
that FDG-labeled RBC can be used to image the myocardium in a streptozotocin (STZ) induced
diabetes rat model under both rest and pharmacologic stress conditions. Compared with normal

vii

age-matched control rats, significant decreases in pharmacologic induced vasodilatory response
in the myocardium of the diabetic rats could be detected.
The results provide evidence that this method can be used to visualize differences in
myocardial microvascular response to pharmacologic stress conditions in healthy rat diabetic rat
myocardium in vivo. This work presents evidence that the 18F-FDG labeling RBC PET image
technique may have valuable application for non-invasive PET imaging of various perfusion and
vascular disease processes.

viii

Chapter 1: Introduction
1.1 Background
Heart disease, dementia, and stroke, as significant public health issues, are leading causes
of mortality and morbidity worldwide [1]. According to the American Heart Association report,
the average annual cost of cardiovascular disease and stroke in the USA was about $351.2 billion
from 2014 to 2015 [2]. According to the 2018 National Diabetes Statistic Report, approximately
10.5% of the US population has diabetes [3]. Diabetes mellitus is a long-term multifactorial
disease associated with a number of vascular complications. It is a significant health problem
worldwide and one of the leading causes of death in the United States. Cardiac vascular
dysfunction is a severe complication of diabetes and is a significant cause of mobility and
mortality in diabetic patients.
Abnormalities in blood perfusion and vascular structures are seen in various pathologies,
including cerebrovascular disease like stroke, atherosclerosis, hypertension, and dementia;
cardiovascular disease like diabetes, peripheral artery disease, vasculitis, and tumor angiogenesis.
Imaging perfusion/vascular abnormalities in these patients often plays an essential role in clinical
diagnosis and treatment decisions. Microvascular disease (MVD) is a type of vascular disorder
disease phenotypes affecting the small arteries, venules, and capillaries in various organs [4, 5].
MVD is widely found in vital organs like the brain, heart, and kidney [5-9]. Unfortunately,
MVD-specific detection methods are limited, making the early diagnosis of MVD challenging.
As such robust MVD-specific screening tests would be expected to improve diagnosis and
management of MVD.
1

In the heart, coronary microvascular disease (CVD) can occur with or without obstructive
epicardial coronary artery disease, which may be leading to ischemia and angina [10-13].
Catheter-based invasive imaging techniques like coronary flow reserve (CFR) and index of
microcirculatory resistance (IMR) are accepted as measures of myocardial blood flow and even
microvascular disease, but CFR lacks the ability to distinguish epicardial from microvascular
disease and largely limited to invasive coronary angiography [14, 15]. Currently, there are
non-invasive modalities like echocardiography, computed tomography (CT), single photon
emission tomography (SPECT,) positron emission tomography (PET), and cardiac magnetic
resonance (MR) that have been used to understand cardiovascular dysfunction [16]. Microbubble
based contrast echocardiography can be used to quantify absolute myocardial blood flow (MBF)
in a large epicardial vessel (left anterior descending coronary artery), but these measurements are
susceptible to operator dependent differences, require sufficient acoustic window access that
may be limited by patient body habitus or comorbidities, and are largely confined to
characterizing epicardial artery stenosis-related flow abnormalities [16-18]. Transthoracic
Doppler echocardiography has an excellent approach to calculate the coronary flow velocity
reserve but with limited use in nonobstructive coronary artery disease [19, 20]. Cardiac magnetic
resonance (CMR) and Computed tomography (CT) are also available for non-invasive MVD
detection by quantitative MBF measurements [21]. Nevertheless, iodine-based contract CT has
high radiation exposure and limited nonobstructive CAD detection ability. Furthermore, iodine
signal intensity in CT imaging does not correlate linearly with concentration, and iodinated
contrast may cause vasodilation leading to overestimated MBF. Gadolinium signal intensity
CMR imaging also does not correlate linearly with concentration; also, these agents diffuse out
of the vasculature, requiring more complicated compartment/kinetic modeling [22-24].

2

PET, as a thriving imaging technology with high tracer sensitivity, has been shown to
accurately provide quantitative measurements of myocardial perfusion [21, 25]. PET perfusion
tracers Rubidium-82, 13N-NH3, and 15O-H2O have good application in absolute quantification of
MBF assessment through artery input function (AIF) kinetic modeling. However, these PET
perfusion agents have a suboptimal clinical implementation, as they have either restricted
availability due to the very short half-life and require more complicated compartment/kinetic
modeling [26-28].
1.2 Common Clinical Blood Perfusion and Vascular Imaging Modalities
Gamma camera-based imaging of radiolabeled red blood cells is commonly used for
imaging the blood pool in clinical nuclear medicine. For example,
blood cells and

99m

Tc-labeled human red

99m

Tc-labeled human serum albumin blood pool imaging with single photon

emission computed tomography (SPECT) or planar scintigraphy have been used to evaluate
cardiac function [29-31], gastrointestinal hemorrhage [32], vascular abnormalities [33], and
orbital cavernous hemangioma (OCH) [34]. Because PET scanners have superior nuclear tracer
sensitivity and image resolution compared to clinical gamma-camera scintigraphy and SPECT
scanners [35], the development of a robust PET-based blood pool imaging technique has a
significant clinical interest. Multiple PET tracers have been proposed as blood perfusion imaging
agents but suffer from certain limitations. For example, 15-oxygen-labeled (15O) H215O,
11-carbon-labeled (11C) 11C-Acetate, 82-rubidium chloride (82Rb), and 13-nitrogen-labeled (13N)
13

NH3 have been used to investigate myocardial blood flow but are not widely used clinically, as

the short radioactive half-life of 15O (122 seconds), 11C (20.334 minutes), 13N (9.97 minutes), and
82

Rb (76 seconds) require the presence of a cyclotron in close proximity to the PET scanner or

access to an

82

Rb generator [36-38]. Due to the positron emitter, 18-fluorine (18F) has a decay
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half-life (108 minutes) which is well-suited for clinical imaging, 18F-based tracers are considered
attractive for PET imaging, especially given the wide spread prevalence of FDG-specific PET
imaging for oncology patients, as well as other

18

F-based agents, such as

18

F-fluorothymidine

(18F-FLT) used for visualizing tumor proliferation[39] .
Computed tomographic angiography (CTA) and magnetic resonance angiography (MRA)
are widely used in the clinical setting for the advantages of rapid image acquisition and high
resolution blood vessels/tissue delineation, which plays an important role in surgical planning.
However, the limitations are that absolute blood flow quantification is not straightforward and
parameter dependent, repeat imaging with contrast agent injection is not feasible/practical, and
characterization of the microvasculature is limited. Microbubble-enhanced ultrasound has a good
application in cardiac, cerebrovascular, and peripheral vascular Doppler imaging to assess both
functional and structural cardiac abnormalities like cardiac ejection fraction, cardiac
enlargement/wall thickness, cardiac valvular disease, cardiac wall motion abnormalities.
However, it has a small acoustic window with limited acoustic access to specific body parts like
obesity, gas-filled structures (bowel), overlying bony structures and is also subject to
operator-dependent variability. Gamma camera planar blood perfusion and SPECT myocardial
perfusion imaging by using Tc-99m labeled red blood cells have wide applications in occult
gastrointestinal

bleeding,

cardiac

function,

and

perfusion

imaging

for

myocardial

ischemia/infarction. It has good use in cardiac perfusion imaging, commonly used to detect
stress-induced myocardial ischemia. However, the majority of clinically used SPECT scanners
have significantly lower sensitivity and spatial resolution compared to positron emission
tomography (PET) and is not practical for absolute blood flow measurements. Widespread
clinical PET imaging is performed with common PET tracer

18

F-Fluorodeoxyglucose (FDG), a

4

glucose analog that is widely used in oncology detection, cerebral metabolic imaging (stroke,
dementia, systemic diseased), and cardiac metabolic imaging.
In this work, we describe the method for labeling human RBC with FDG and washing the
FDG-labeled RBC. We also describe the injection of labeled RBC into splenectomized NSGTM
immunodeficient mice and subsequent imaging of the mouse vasculature using a small animal
microPET/CT platform. Given that the erythrocyte labeling and washing procedure is
straightforward and that the FDG leakage rate from labeled erythrocytes is relatively slow (~10%
in 46 minutes), we believe this method allows for robust PET imaging of the mouse vasculature.
We believe that this imaging technique would be of interest to investigators seeking to visualize
the vasculature of immunodeficient mice for other applications. In addition, we speculate that
this technique would offer significant advantages over

99m

Tc-based nuclear blood pool imaging

for the evaluation of occult gastrointestinal bleeding in patients and may be helpful for
evaluating other clinical pathologies, including those involving the cerebral and myocardial
vasculature.
FDG has a wide application in clinical in quantitative measurements of cardiovascular
activity with an ideal half-life. Our research determined that 18F-FDG labeled red blood cells
provided a flexible method to image vascular blood perfusion in mice and rats. In this study, we
investigated 18F-FDG labeled rat red blood cells (RBC) PET images to visualize the
microvascular value under both rest and pharmacologic stress conditions in healthy rats and
microvascular abnormalities in infarcted myocardium and diabetic rat model.
1.3 Hypothesis, Research Goal
The overall goal of this work is to develop and characterize a PET-based imaging method
in small animal models that can be rapidly transferred to the clinical setting to image

5

abnormalities in blood perfusion, vascular structure, as well as vascular dysfunction in various
organs. This work presents evidence that FDG-labeled RBC PET imaging can be used to
visualize the entire vasculature of mouse and rat models, including the microvasculature.
Generally, there is no microvascular dysfunction (MVD) specific imaging technique. In
this study, we provide an excellent approach to image the microvascular directly. Furthermore, it
was possible to detect the MVD in myocardial dysfunction due to diabetes and infarction.
There are three hypotheses related to the research question. Hypothesis 1: FDG can label
human RBCs with high efficiency in a fairly rapid and facile manner, with grossly stable
intracellular FDG localization suitable for in vivo imaging of the total vasculature. Hypothesis 2:
Pharmacological-induced increases in the rat myocardial and cerebrovascular blood volume can
be indirectly visualized as areas of increased intravascular tracer activity with FDG RBC PET
imaging, Hypothesis 3: MVD can be semi-quantitatively characterized by FDG RBC PET
imaging, including within affected microvasculature in a myocardial infarction rat model, and
diabetic induced myocardial MVD.
1.4 Ethics
All experiment procedures were approved by the University of South Florida (USF)
Institutional Animal Care and Use Committee (IACUC). All experiments were performed in
accordance to federal regulations and USF IACUC principles and procedures. For radiation
safety, rats were placed in a clean microisolator, and then the cage was placed within a ventilated
cabinet enclosed by 2 inches of lead to allow decay of isotope tracer by 11 half-lives. For the
FDG-labeled red blood cells, 18F has a half-life of 110 minutes, so that animals were kept within
the shielded cabinet for 21-24 hours. Contaminated bedding was appropriately discarded as
radioactive waste. Cages and animals were screened with a gamma Geiger counter to validate

6

background levels of radioactivity before undergoing euthanasia. The room used for experiments
contained all appropriate supplies and equipment for these procedures (e.g., safety goggles with
leaded glass, lead-lined solid and liquid waste receptacles, and lead-lined refrigerator/freezer). If
an animal died during the experiment, the carcass was bagged and held in the shielded
refrigerator for 11 half-lives prior to disposal. Solid and liquid waste disposal was done in
accordance with USF Radiation Safety requirements.

7

Chapter 2: Experiment Design
This chapter was published in Bio-protocol[40]. Permission is included in Appendix A.
2.1 Materials and Reagents
1. 1.8 ml cryovial tube (Thermo Fisher Scientific, Thermo ScientificTM, catalog number:
343958)
2. 3.5 ml cryovial tube (Thermo Fisher Scientific, Thermo ScientificTM, catalog number:
343958)
3. 15 ml conical tube (Corning, catalog number: 430790)
4. 1 ml sterile syringe (NIPRO Medical Corporation, catalog number: JD+01D2238)
5. 10 cc BD Luer-LokTM disposable syringe (Thermo Fisher Scientific, catalog number: BD
309604)
6. 15 ml FalconTM conical centrifuge tube (Thermo Fisher Scientific, catalog number:
14-959-53A)
7. 10 ml and 25 ml FisherbrandTM Sterile Polystyrene Disposable Serological Pipets (Thermo
Fisher Scientific, catalog numbers: 13-676-10F and 13-676-10M )
8. 22 gauge needle (BDTM Needle 1, BD, catalog number: 305155).
9. 26 gauge x ¾” mouse and rat tail vein Monoject IV catheter (Patterson Veterinary, catalog
number: 07-836-8403)
10. ParafilmTM M PM996 all purpose laboratory film
11. 200 µl and 1,000 µl TipOne sterile filter pipet tips (USA Scientific, catalog numbers:
1120-8810 and 1122-1830)
8

12. 0.2 µm Nalgene® bottle top sterile filter unit (Sigma-Aldrich, catalog number:
Z370576-12EA)
13. 4-8 weeks old male splenectomized NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSGTM)
immunodeficient mice (The Jackson Laboratory, stock number: 005557)
14. 10 ml of human whole blood in standard ACD anticoagulant solution shipped next day
(Zen-Bio, Inc, SER-WB10ML-SDS)
15. 1 ml of 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) with specific activity calibrated at a
minimum of 20 milliCuries/ml at the time of cell labeling (United States Pharmacopeia
(USP) grade, Cardinal Health nuclear pharmacy)
16. 0.9% Sodium Chloride Injection USP, 100 ml Fill in 150 ml PAB® (B. Braun, NDC
number: 00264-1800-32)
17. 250 ml bottle of IsoThesia (Isoflurane) solution (Henry Schein Animal Health, catalog
number: 029405)
18. Sterile de-ionized water
19. NaCl (Sigma-Aldrich, catalog number: S7653-1KG)
20. KCl (Sigma-Aldrich, catalog number: P9333-1KG)
21. K2EDTA dihydrate (Sigma-Aldrich, catalog number: 03660-1KG)
22. EDTA solution 5x (see Recipes)
23. EDTA solution 1x (see Recipes)
24. 1 Unit/ml of heparin sodium salt (see Recipes)
25. Heparin sodium salt (Sigma-Aldrich, catalog number: 375095-100KU)
26. Phosphate Buffered Saline (PBS) solution, pH 7.4 (Thermo Fisher Scientific, catalog
number: 10010023)
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2.2 Equipment and Software
1. Inveon PET/CT (Siemens Medical Inc., INVEN, catalog number: 138757)
2. Centrifuge 5810 R (Eppendorf, catalog number: 108308)
3. Centrifuge 5810 R (Eppendorf, catalog number: 119548)
4. 200 µl single channel manual pipetter
5. 1,000 µl single channel manual pipetter
6. AtomLabTM 500 dose calibrator (Biodex Medical Systems, Inc)
7. Tissue culture incubator (Sanyo Scientific, catalog number: 133060)
8. Biological safety cabinet (The Baker company, SterilGARD, catalog number: 101951)
9. Rotator platform (Labnet International, Inc GYROMINI)
10. Matlab (Matlab software package, 2018 version)
11. Microsoft Excel program (Microsoft Excel 2010)
12. Inveon PET/CT small animal imaging platform (Siemens Medical Inc., Knoxville,
Tennessee)
13. BioVet® (m2m Imaging) physiological monitoring and heating system (m2m imaging
Corp. USA. www.m2mimaging.com)
2.3 Procedure
2.3.1 Red Blood Cell (RBC) Preparation
Gently aspirate the whole blood in standard anticoagulant citrate dextrose (ACD) solution
(overnight shipping from Zen-Bio, Inc) into a sterile 15 ml conical centrifuge tube by a 10 ml
sterile disposable pipet. The original blood sample should have a good quality shown in Figure
2.1.
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Figure 2.1 The original anti-coagulated blood sample should have no clot and have good fluidity.
Reprinted from “Imaging the Vasculature of Immunodeficient Mice Using Positron Emission
Tomography/Computed Tomography (PET/CT) and 18F-fluorodeoxyglucose Labeled Human
Erythrocytes.” by Wang, S. and Choi, J. W. 2019, by Copyright: © 2019 Wang, S. and Choi, J. W,
retrieved: https://bio-protocol.org/ 10.21769/BioProtoc.3391., Reprinted with permission.
Blood should be slowly pipetted to minimize mechanical trauma/shear injury to
erythrocytes. Centrifuge blood at 1,000 times Earth’s gravitational force (1,000 x g) 10 min in
the desktop centrifuge (no brake) at room temperature.
Slowly aspirate nearly all of the plasma or supernatant from the red blood cell (RBC)
fraction using a 1 ml sterile pipet. The plasma should be close to straw-colored or have a slightly
reddish tinge, as Figure 2.2. The plasma that has a frankly turbid or significant reddish coloration
implies either improper centrifugation or significant pre-existing hemolysis of the original blood
sample that may render the sample unsuitable for radiotracer labeling. Slowly transfer 2 ml of
pelleted RBCs into 15 ml conical centrifuge tube using 10 ml sterile pipet. Residual plasma and
buffy coat should be avoided during erythrocyte aspiration. Add 8 ml of 1x EDTA solution to
RBCs. Close cap on the tube and gently invert tube several times to wash cells.
11

Figure 2.2 The original blood after the first centrifuge step. Ideally, the plasma should be close to
straw colored or have a slightly reddish tinge. Reprinted from “Imaging the Vasculature of
Immunodeficient Mice Using Positron Emission Tomography/Computed Tomography (PET/CT)
and 18F-fluorodeoxyglucose Labeled Human Erythrocytes.” by Wang, S. and Choi, J. W. 2019,
by Copyright: © 2019 Wang, S. and Choi, J. W, retrieved: https://bio-protocol.org/
10.21769/BioProtoc.3391., Reprinted with permission.

Centrifuge 1,000 x g 10 min at room temperature, then slowly aspirate the supernatant
which is shown in Figure 2.3. with a 10 ml sterile pipet. Rapid supernatant aspiration will disturb
the supernatant/RBC interface and result in aspiration of RBCs.
Transfer 250 µl of RBCs with 1,000 into µl pipet tip into 1.8 ml cryovials. Care should be
taken to avoid pipetting any residual supernatant.
To each RBC cryovial, add 100 µl 5x EDTA solution and 50 µl sterile de-ionized water
(total volume = 400 µl) via a manual pipette.
2.3.2 18F-FDG Labeling of RBC
To maximize the radiolabeling efficiency of RBCs for in vivo PET imaging of the
vasculature of rat/ mice, the specific activity of USP grade
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F-FDG should be calibrated to at

least 20 milliCurie (mCi) per ml at the start of cell labeling.
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Add 100 µl

18

F-FDG solution to each RBC cryovial (F.V. = 500 µl) behind appropriate

radioactivity shielding. Methods for handling radioactive materials for this protocol should
follow those established by the radiation safety officer at your institution. Directly count
radioactivity in each cryovial using the AtomLabTM dose calibrator (mCi’s) and record the time.
The amount of activity should be at least 1 mCi of FDG in each vial. Ensure the cap is tightly
screwed on the cryovial. Care need be taken when choosing an appropriate vial for FDG RBC
labeling, as some cryovials are composed of certain plastics that do not maintain a good seal
about the cap when exposed to higher temperatures and can result in local radioactivity
leakage/contamination. A thin strip of ParafilmTM can be wrapped around the margins of the cap
to ensure no radioactivity leakage from the tube and reduce water loss from the cryovial lumen.

Figure 2.3 The RBCs after washing with 4x volume of 1x EDTA solution. Reprinted from
“Imaging the Vasculature of Immunodeficient Mice Using Positron Emission
Tomography/Computed Tomography (PET/CT) and 18F-fluorodeoxyglucose Labeled Human
Erythrocytes.” by Wang, S. and Choi, J. W. 2019, by Copyright: © 2019 Wang, S. and Choi, J. W,
retrieved: https://bio-protocol.org/ 10.21769/BioProtoc.3391., Reprinted with permission.
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Figure 2.4 RBCs labeled with 100 µl 18F-FDG solution on rotator platform and placed in an
upright position in the 37 °C incubator. (Reprinted from “Imaging the Vasculature of
Immunodeficient Mice Using Positron Emission Tomography/Computed Tomography (PET/CT)
and 18F-fluorodeoxyglucose Labeled Human Erythrocytes.” by Wang, S. and Choi, J. W. 2019,
by Copyright: © 2019 Wang, S. and Choi, J. W, retrieved: https://bio-protocol.org/
10.21769/BioProtoc.3391., Reprinted with permission.)

Gently finger resuspend RBCs. Place vials in an upright position in a tube rack tied/taped
to a rotator platform, as Figure 2.4. Incubate rotating samples in an upright position at 37 °C for
30 min at ≤ 60 RPM. Avoid inverting the tube during rotation, as this likely increases the amount
of dried cells adherent to the tube wall.
Centrifuge RBC samples at 1000 x g 10 min (no brake) at 4 °C. The present sample is
shown in Figure 2.5. Place samples in a ventilated laboratory hood behind appropriate
radioactivity shielding and gently transfer the supernatant (about 250 µl) to a 3.5 ml cryovial
labeled“SUPE 1 and 2”.
14

Gently resuspend each 250 µl RBC cell pellet in 1 ml 1x EDTA solution via manual
pipette. Care should be taken to resuspend cells slowly to minimize pipet-induced mechanical
damage/shear injury to cells. Repeat centrifugation of RBC samples at 1,000 x g 10 min (no
brake) at 4 °C. The centrifuged sample is shown in Figure 2.6.

Figure 2.5 The free 18F-FDG fraction (clear upper half of solution) and the precipitated RBCs
fraction (red bottom half of the solution). Reprinted from “Imaging the Vasculature of
Immunodeficient Mice Using Positron Emission Tomography/Computed Tomography (PET/CT)
and 18F-fluorodeoxyglucose Labeled Human Erythrocytes.” by Wang, S. and Choi, J. W. 2019,
by Copyright: © 2019 Wang, S. and Choi, J. W, retrieved: https://bio-protocol.org/
10.21769/BioProtoc.3391., Reprinted with permission.
Transfer 2nd supernatant to appropriate “SUPE” tube. Gently resuspend 250 µl RBCs cell
pellets again in 1 ml 1x EDTA solution, as described above. Repeat centrifugation of RBC
samples at 1,000 x g 10 min (no brake) at 4 °C.
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Figure 2.6 Centrifuged 18F-FDG-labeled RBC sample after washing with 1 ml 1x EDTA
solution. Reprinted from “Imaging the Vasculature of Immunodeficient Mice Using Positron
Emission Tomography/Computed Tomography (PET/CT) and 18F-fluorodeoxyglucose Labeled
Human Erythrocytes.” by Wang, S. and Choi, J. W. 2019, by Copyright: © 2019 Wang, S. and
Choi, J. W, retrieved: https://bio-protocol.org/ 10.21769/BioProtoc.3391., Reprinted with
permission.
Transfer supernatant to appropriate “SUPE” tube. Carefully pipet residual supernatant
from the interface with the cell pellet, leaving only a tiny meniscus overlying the pellet.
Directly count SUPE and RBC pellet cryovials using AtomLab detector via dose
calibrator (µCurie) and record time. Typical amounts of intracellular radiotracer activity is
limited by the total allowable volume of cell solution (250 µl pelleted RBCs) that can be injected
into a mouse per day as per our institutional IACUC guidelines, but usually range from ~150 to
300 µCuries, and can be higher depending upon the chosen 18F-FDG specific activity at the start
of cell labeling. Gently resuspend the pellet in 250 µl of 1x EDTA solution. The labeling of two
RBC samples allows for titration of a larger volume of labeled RBCs, as needed.
Transfer the RBC suspension to a 1 ml syringe using a 22 gauge needle. Any residual
clumps of cells should not be aspirated, as these likely represent damaged/coagulated cells. Cells
should be slowly aspirated into the syringe lumen to minimize mechanical damage/shear injury
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to cells. The radioactivity in the syringe should be measured before and after animal injection to
determine net activity injected in vivo, as there will be residual activity left in the syringe after
injection.
2.3.3 Small Animal PET/CT Imaging
Prepare

4-6

week-old

male

splenectomized

NODSCIDgamma

(NSGTM)

immunodeficient mice for the experiment.
The mouse can be fasted the night before PET/CT imaging to encourage shifting of
mouse metabolic activity from glucose to fatty acids, thus minimizing myocardial uptake of any
free FDG in the labeled cell preparation. The mouse/rat can also be placed on a very low
carbohydrate diet for this purpose as well, as needed. Draw 500 µl of mouse blood through retro-

Figure 2.7 Example for drawing blood through rat leg venous. Reprinted from “Imaging the
Vasculature of Immunodeficient Mice Using Positron Emission Tomography/Computed
Tomography (PET/CT) and 18F-fluorodeoxyglucose Labeled Human Erythrocytes.” by Wang, S.
and Choi, J. W. 2019, by Copyright: © 2019 Wang, S. and Choi, J. W, retrieved:
https://bio-protocol.org/ 10.21769/BioProtoc.3391., Reprinted with permission.
-orbital venous plexus puncture or other approved venous blood draw at your institution， as
seen in the example shown in Figure 2.7. Blood should be collected into the heparinized blood
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collection tube. If the blood is drawn too slowly, there is a risk of significant coagulation
occurring, rendering the blood sample unsuitable for FDG labeling. Measure blood glucose level
with a blood glucose monitor for PET calibration.
Anesthetize the mouse via a nosecone manifold under 2-4% inhalational isoflurane. The
lowest level of inhalational isoflurane possible is recommended, as isoflurane may induce
vasodilation of the mouse vasculature. Record the level of inhalational isoflurane used per
mouse.Warm the mouse tail with either a warm soaked towel to stimulate dilation of the mouse
tail veins. Insert a tail vein micro-catheter into one of the dilated mouse tail veins. Flush tail vein
catheter with 1 U/ml heparin-PBS solution.

Figure 2.8 Placement of animal in microPET/CT scanner bed for 18F-FDG RBC imaging of the
whole body vasculature. Reprinted from “Imaging the Vasculature of Immunodeficient Mice
Using
Positron
Emission
Tomography/Computed
Tomography
(PET/CT)
and
18F-fluorodeoxyglucose Labeled Human Erythrocytes.” by Wang, S. and Choi, J. W. 2019, by
Copyright: © 2019 Wang, S. and Choi, J. W, retrieved: https://bio-protocol.org/
10.21769/BioProtoc.3391., Reprinted with permission.
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Secure the mouse onto the micro-PET/CT scanner bed under 2-4% inhalational isoflurane
anesthesia via nose-cone manifold. The animal can be secured to the micro-PET/CT scanner bed
by gently wrapping the animal in bubble packaging to minimize animal movement and preserve
body warmth. Care must be taken when wrapping the animal, as tight wrapping may impede
animal respiratory motion, as shown in Figure 2.8.
Slowly inject 500 µl of FDG-labeled human erythrocyte suspension into the mouse/rat
through the tail vein microcatheter over the course of 1 min to minimize shear injury to cells
from passage through the microcatheter lumen. See the example shown in Figure 2.9.
Acquire ECG-gated whole body images of the mouse, followed by CT calibration images.
PET/CT image acquisition parameters will depend upon the particular experimental indications
and unique imaging platform set up at a given institution; as such, the following is a description
of the protocol used at our institution. Place electrocardiogram (ECG) leads on two front limbs
and one hind limb of the mouse (ground lead on a rear leg) for ECG gated PET imaging.

Figure 2.9 Example of injection of FDG-labeled RBC through tail vein microcatheter. Reprinted
from “Imaging the Vasculature of Immunodeficient Mice Using Positron Emission
Tomography/Computed Tomography (PET/CT) and 18F-fluorodeoxyglucose Labeled Human
Erythrocytes.” by Wang, S. and Choi, J. W. 2019, by Copyright: © 2019 Wang, S. and Choi, J. W,
retrieved: https://bio-protocol.org/ 10.21769/BioProtoc.3391., Reprinted with permission.
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The signals detected by these electrodes are recorded during the 10 minutes time period by
BioVet® (m2m Imaging) physiological monitoring and heating system. Set the threshold for TTL
cardiac gating signals in a rising mode of R-wave peak. Reconstruct the PET list-mode data using
3D-OSEM iterative algorithm with four iterations and eight subsets, with a final image volume of
256 x 256 x 256 voxels. Set effective voxel effective dimensions at 1.4 x 1.4 x 1.4 mm. For each
animal, there are three data sets: dynamic 3D PET reconstruction with 30 frames; standard
3-dimensional (3D) PET reconstruction, resulting in a motion–time average 3D PET image; and
the phase-based 4-dimensional (regular 3-dimensional plus time, 4D) PET cardiac reconstruction,
with four cardiac gate binning. Please see Figure 2.10. and 2.11. In all cases, CT attenuation
correction is applied to the PET images (Choi et al., 2019).

Figure 2.10 Example for microPET acquisition set up. Reprinted from “Imaging the Vasculature
of Immunodeficient Mice Using Positron Emission Tomography/Computed Tomography
(PET/CT) and 18F-fluorodeoxyglucose Labeled Human Erythrocytes.” by Wang, S. and Choi, J.
W. 2019, by Copyright: © 2019 Wang, S. and Choi, J. W, retrieved: https://bio-protocol.org/
10.21769/BioProtoc.3391., Reprinted with permission.
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2.4 Data Analysis
2.4.1 Micro-PET/CT Analysis
PET/CT image processing/analysis parameters will depend upon the particular
experimental indications and unique imaging platform set up at a given institution; as such, the
following is a description of the protocol used at our institution. Analyze the whole body PET
images of the mouse using Inveon Workstation Software (Siemens Medical Inc., Knoxville,
Tennessee). Select the vendor software-supplied Patlak compartment plot option for kinetic
modeling. For 3D PET and 4D PET data sets, manually select multiple volumes of interest (VOI)
based on corresponding CT images for the following organs (as needed): heart, leg muscle, liver,
kidney, and brain. Voxel activities are represented in standardized uptake values (SUV). Plot
dynamic activity curves for VOIs using dynamic 3D PET data set for each animal.

Figure 2.11 Example for microCT acquisition set up using Siemens Inveon platform. Reprinted
from “Imaging the Vasculature of Immunodeficient Mice Using Positron Emission
Tomography/Computed Tomography (PET/CT) and 18F-fluorodeoxyglucose Labeled Human
Erythrocytes.” by Wang, S. and Choi, J. W. 2019, by Copyright: © 2019 Wang, S. and Choi, J. W,
retrieved: https://bio-protocol.org/ 10.21769/BioProtoc.3391., Reprinted with permission.
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The 4D PET data are used for defining cardiac function. First, segment the heart on CT
images based on anatomical features, then transfer the segmented volume (cardiac PET VOI) for
image co-registration, as seen with the example shown in Figure 2.12. Images are represented as
maximum intensity projection (MIP) reconstructions of the source data. ECG-guided binning of
PET MIP images can be performed to obtain pseudo-dynamic images of mouse cardiac
contractility.
2.4.2 Labeling Efficiency Calculation
Labeling efficiency = (radioactivity dose of RBC pellet)/(radioactivity dose of SUPE +
radioactivity dose of RBC pellet)

Figure 2.12 Example of basic parameter setup for microPET/CT reconstruction on Siemens
Inveon workstation. Reprinted from “Imaging the Vasculature of Immunodeficient Mice Using
Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-fluorodeoxyglucose
Labeled Human Erythrocytes.” by Wang, S. and Choi, J. W. 2019, by Copyright: © 2019 Wang,
S. and Choi, J. W, retrieved: https://bio-protocol.org/ 10.21769/BioProtoc.3391., Reprinted with
permission.
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2.5 Recipes
1. Filter sterilized 100 ml 5x EDTA solution
700 mM NaCl
20 mM KCl
12.5 mM K2EDTA dihydrate. Add sterile de-ionized water to a final volume of 100 ml
Pass final solution through 0.2 micrometers (µm) Nalgene bottle top sterile filter unit
2. 100ml 1x EDTA solution
20 ml of filter sterilized 5x EDTA solution
80 ml of sterile di-ionized water
Pass final solution through 0.2 micrometer (µm) Nalgene bottle top sterile filter unit
3. 1 Unit/ml of heparin-PBS solution
Heparin sodium salt dissolved in sterile Phosphate Buffered Saline (PBS) solution, pH
7.4.
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Chapter 3: Pharmacological-induced Increases in Myocardial and Cerebral Blood Value
Measurement
3.1 Research Purpose
Compared to dominant clinical planar scintigraphy and single-photon emission computed
tomographic (SPECT) blood perfusion imaging platforms. PET has significant advantages in
imaging quality and resolution sensitivities. We seek to show that FDG-labeled red blood cells
can be used to image the vasculature in mice and rats and measure the rat myocardial and
cerebral blood volume before and after pharmaceutical stress drug-induced vascular dilation.
This study presents a novel imaging technique for imaging heart muscle and cerebral vascularity.
The purpose of this chapter study is to determine if the FDG-labeled rat red blood cells can also
be used to measurement changes in blood volume to the rat heart and the brain after
administration of the pharmaceutical drug regadenoson and acetazolamide.
Regadenoson is a selective short-acting adenosine A2A receptor agonist that stimulates
vasodilation of the coronary arteries [41]. This drug is widely used in the clinical setting to
induce pharmacologic "stress" of the heart in patients undergoing SPECT myocardial perfusion
imaging. In this work, this drug is to be administered via the tail vein catheter in order to
determine if FDG-labeled cells can detect the increase in rat myocardial vascular volume after
administration of this drug.

Detecting small changes to the volume of the myocardium with this

method could potentially be used to diagnose different types of cardiac vascular dysfunction,
including infarction and diabetic-induced cardiomyopathy. Aminophylline is an adenosine
receptor antagonist that is administered to rats to reverse the vasodilatory effects of the drug
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Regadenoson [42]. This will allow PET imaging of the rats under initial pharmacologic stress
(Regadenoson) imaging, reversal of Regadenoson effects with aminophylline, followed by "rest"
imaging. Acetazolamide is known to dilate brain vessels, resulting in increased blood perfusion
to the brain[43]. Detecting small changes in blood volume to the brain with this technique could
potentially be used to diagnose different types of dementia, including Alzheimer's disease.
For purposes of improving the myocardial chamber and ventricular wall segmentation,
the same protocol for imaging the myocardium and blood pool will be used as described in the
original protocol, but with the additional injection of 0.8 ml's (80 mg) of 15 nm Aurovist gold
nanoparticles prior to FDG-labeled RBC injection. The gold nanoparticles allow for more
accurate volumetric measurement of the left ventricular muscle needed to segmentation FDG
RBC PET activity in the myocardial.
3.2 Experiment Procedure
3.2.1 Stress and Rest Myocardial Blood Perfusion Imaging Process
Secure the rat onto the micro-PET/CT scanner bed under 2-4% inhalational isoflurane
anesthesia via a nose-cone manifold. The animal can be secured to the micro-PET/CT scanner
bed by gently wrapping the animal in bubble packaging to minimize animal movement and
preserve body warmth.
The ability to measure myocardial perfusion with FDG-RBC PET imaging would
potentially allow for the detection of myocardial microvascular disease. The procedure is as
follows: Non-lethal rat blood phlebotomy samples were collected via a saphenous vein or
subclavian vein after anesthesia into an anticoagulant (heparin) container. Alternatively,
retro-orbital phlebotomy can be performed, as initial phlebotomy experiences with these rats
using the saphenous vein approach may sometimes be difficult.
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Rat red blood cells are purified and then labeled with the PET tracer FDG. A tail vein
catheter is placed into the rat under anesthesia. FDG-labeled rat red blood cells are then injected
through a tail vein catheter, then injected with the coronary vasodilator drug Regadenoson
(Sigma Aldrich, St. Louis, MO) (25 μg/kg in 100 μl 1x EDTA solution) to induce pharmacologic
stress of the heart, and then undergo microPET imaging for 15-20 minutes and CT 5-10 minutes.
After that, the rat was injected with Aminophylline (Sigma Aldrich, St. Louis, MO) (40 mg/kg in
200 μl DI water) to reverse the myocardium vasodilation. Following by 15-20 minutes microPET
imaging and 5-10 minutes of CT imaging.
After a sufficient number of imaging experiments have been completed to obtain
statistically significant results, the rats will be euthanatized under inhalational anesthesia.
3.2.2 Stress and Rest Cerebral Blood Perfusion PET/CT Imaging Process
The design for the procedure to image rat cerebral blood perfusion is very similar to the
original protocol; it is as follows: Non-lethal rat blood phlebotomy samples collected as
according to the original protocol or collected via subclavian vein after rat got anesthesia. Rat red
blood cells are purified and then labeled with the PET tracer FDG. A tail vein catheter is placed
into the anesthetized rat. FDG-labeled rat red blood cells are then injected through the tail vein
catheter. Then undergo microPET imaging for 15-20 minutes and CT 5 -10 minutes. After that,
the rat was injected with the pharmacological vasodilation drug Acetazolamide (Sigma Aldrich,
St. Louis, MO) (100mg/kg in 200 μl Dimethyl sulfoxide (DMSO) buffer) to induce cerebral
vasodilation. The vasodilator acetazolamide is then injected through the catheter, and an
additional microPET imaging for 15-20 minutes and CT 5 -10 minutes is performed to image the
rat brain. After a sufficient number of imaging experiments have been completed to obtain
statistically significant results, the rats will be euthanatized under inhalational anesthesia.
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3.2.3 Gold Nanoparticle Enhanced Contrast Myocardial CT Imaging
A tail vein microcatheter is placed into the anesthetized rat. And then, secure the rat onto
the micro-PET/CT scanner bed under 2-4% inhalational isoflurane anesthesia via a nose-cone
manifold. Injection of 0.4 ml's (80 mg) of 15 nm Aurovist gold nanoparticles (Sigma Aldrich, St.
Louis, MO) through the microcatheter prior to CT and then undergo CT scanning 5-15 minutes.
3.2.4 RBC Damage Measurement by Flow Cytometry
To measure the degree of mechanical RBC membrane damage induced by multiple
washing and centrifugation steps in the FDG labeling RBC process. The RBC samples were
evaluated by Annexin V-PE and Calcein-AM double-labeling flow cytometric analysis,
acetoxymethyl ester of calcein (Calcein-AM) (Sigma Aldrich, St. Louis, MO), a fluorescein dye
maker for cell membrane integrity and viability[44]. Annexin-V-phycoerythrin (Annexin V-PE)
(Sigma Aldrich, St. Louis, MO) is an early eryptosis fluorescein marker [45].
Remove supernatant and buffy coat after centrifuging the blood at 1000 x g for 10
minutes. Re-suspend the RBC pellet in 4 x value of 1x EDTA solution and spin it 1000 x g for 10
minutes, and then remove the supernatant. The blood was divided into three groups, each group
experiment repeated at least three times.
FDG labeling RBC test group measurement: after mock the FDG labeling procedure.
Using the equivalent value of 1 x EDTA buffer solution for FDG. Incubate the blood at 37°C for
30 minutes, and then wash with 4 x value of 1 x EDTA solution for two times and centrifuge
three times. Dilute approximate 4 x 105 RBC in 1 x PBS buffer sample to a volume of 80 µl. Add
80 µM Calcein AM dye, 10 µl Annexin V-PE and 400 µl 1x Annexin V bind buffer. Incubate the
samples at 37°C for 90 minutes in the dark. Positive and negative control group: dilute
approximate 4 x 105 unperturbed RBC in 1 x PBS buffer sample to volume of 80 µl. Add 80 µM
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Calcein AM dye, 10 µl Annexin V-PE and 400 µl 1x Annexin V bind buffer. Incubate the sample
in 37°C for 90 minutes in the dark as the positive control group. Dilute approximate 4 x 105
unperturbed RBC in 1 x PBS buffer sample to volume of 70 µl. Add 80 µM Calcein AM dye, 10
µl Annexin V-PE, 10 µl 20mM calcium chloride buffer solution, and 400 µl 1x Annexin V
binding buffer. Incubate the sample in 37°C for 90 minutes in the dark as the negative control
group. Transfer the blood samples to flow cytometry tube and evaluated with flow cytometric
analysis.
3.2.5 FDG Labeling RBC Release Fraction Measurement
In order to evaluate the FDG release ratio from labeled RBC, one-day-old human blood
was labeled with FDG using the previously labeling procedure. The washed 250 µl RBC samples
were incubated with 375 µl plasma in 37°C for 30, 60, and 90 minutes. Centrifuge the samples at
1000 x g for 10 minutes after accurate incubation, and directly count the radioactivity dose of
supernatant and RBC pellet using AtamLab detector via dose calibrator. The release fraction=
radioactivity dose of supernatant / (radioactivity dose of supernatant + radioactivity dose of RBC
pellet). Sample activity counting was made approximately 16 minutes plus the incubation period
after the start of the plasma incubation.
3.3 Results
Myocardial vascular imaging: FDG-RBC PET/CT imaging allows for the detection of
blood perfusion in rat body as Figure 3.1 & 3.3 shows a 3-D view of blood perfusion in rat a
portion of the rat body by FDG RBC PET/CT image. The vascularity in various organs,
including the heart and the brain, and the jugular veins, arteries, brain veins are all visualized in
Figure 3.1; the low-right showed the 3-D fused maximum intensity projection (MIP). The
differences were calculated by digital subtraction of the stress and rest conditions images after
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segmentation of the myocardium as Figure 3.8, coronal and axial segmentation of normal rat
myocardial on FDG RBC PET/CT images for stress and rest conditions, separately. After digital
subtraction of the stress and rest slices as Figure 3.9, the increased value in myocardial
vasculature can be visualized by FDG RBC PET imaging. What is more, the activities in
rest/stress conditions of the heart can be quantified as Figure 3.10 & 3.11 & Table 3.1. We were
able to detect a relative regadenoson-dependent increase in LV intramyocardial vessel volume
with a mean pharmacologic stress-related increase in volume of 52.3% ± 11.3% (Bq/ml) (n=5).
The difference in intramyocardial vascular volume (stress vs. rest) was statistically significant
(two- tailed Wilcoxon signed rank test: U = 0 ≤ 2, α = 0.05, n = 5).
Cerebrovascular imaging: the cerebral vasculature is imaged as Figure 3.2, 3-D view by
RBC microPET/CT image zoom in rat brain. Top-left is the axial orientation view of the rat brain,
and the top-right is the sagittal orientation view of the rat brain, the bottom-left is the coronal
orientation of the rat brain, and the bottom-right fused MIP 3-D view of the rat brain. The
differences were calculated by digital subtraction of the stress and rest conditions images after
segmentation of the brain as Figure 3.4, for stress and rest conditions, separately. After that,
digital subtraction of the stress and rest slices as Figure 3.5, the increased value in cerebral
vascular volume is indirectly visualized by FDG RBC PET imaging. What is more, the activities
in rest/stress conditions of the brain can be quantified as Figure 3.6 & 3.7 & Table 3.1. After
administration of acetazolamide, there is a significant relative vasodilator-induced increase in the
total cerebrovascular volume of 72.2% ± 14.7% (n=6). The difference in stress vs. rest
cerebrovascular volume was statistically significant (two-tailed Wilcoxon signed rank test: U = 0
≤ 2, α = 0.05, n = 6).
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Gold nanoparticle enhanced contrast myocardial CT imaging: the gold nanoparticles
allow for more accurate volumetric measurement of the left ventricular muscle needed to
quantify FDG RBC PET activity in the myocardial vasculature, as shown in Figure 3.12. The
myocardial chamber and ventricular wall are all visualized and easily segmented under the gold
nanoparticles enhanced CT. However, PET imaging is sufficient for myocardium and ventricular
chamber segmentation. The gold nanoparticles enhanced CT was initially pursued to improve
with the myocardial chamber and ventricular wall segmentation but was later not deemed
necessary.
RBC membrane damage assessment by flow cytometry: as Figure 3.13 flow cytometry
for RBC damage measurement results showed, the FDG labeling RBC procedure induced
minimum damage to the RBC. The labeling procedure test group has a very close calcein AM
positive percentage of about 98 % compared with the untreated group about 97% percent calcein
AM positive result. It indicates that this labeling method is safe and straightforward with
minimum FDG damage. Unlike the C：CaCl2-treat group, which has 2.17% calcein AM positive
and 82.03% annexin V-PE positive.
FDG labeling RBC release fraction measurement: the FDG labeling RBC release fraction
measurement is shown in Figure 3.14. It has about 10% release fraction after 46 minutes at the
start point, and it is about 1% percent leakage which is correlated with free FDG residual in RBC
during the pipe removing supernatant procedure. During the 20 minutes of PET scanning. It has
about 5% leakage.
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3.4 Figures and Tables

Figure 3.1 3-D view of blood perfusion by RBC microPET/CT image zoom in rat heart. Top-left
is the axial orientation view of the rat heart, and the top-right is a sagittal orientation view of the
rat heart. Bottom-left is the coronal orientation of the rat heart. Bottom-right is the fused MIP
3-D view of the rat heart.

Figure 3.2 3-D view of blood perfusion by RBC microPET/CT image zoom in rat brain. Top-left
is the axial orientation view of the rat brain, and the top-right is the sagittal orientation view of
the rat brain, the bottom-left is the coronal orientation of the rat brain, and the bottom-right fused
MIP 3-D view of the rat brain.
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Figure 3.3 2-D visualize of blood perfusion in rat body 20 frames by RBC micoPET/CT.

Figure 3.4 Segmentation of rat brain. Left: fused 3-D view of rat brain segmentation, right:
coronal view of rat brain segmentation.
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Figure 3.5 Digital subtraction of stress rest condition rat brain view.

Figure 3.6 Becquerel histograms of rat brain.
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Figure 3.7 Standardized uptake values (SUV) histograms of rat brain.

Figure 3.8 Coronal segmentation of normal rat myocardial on FDG RBC PET/CT images.

Figure 3.9 Stress-rest myocardium short axial view the short axis view of rat left ventricular wall.
Left stress condition, middle, after-stress (rest), right, the difference after subtraction stress and
rest images.
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Figure 3.10 Becquerel histograms of rat heart.

Figure 3.11 Standardized uptake values (SUV) histograms of the rat myocardial.
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Figure 3.12 Gold nano-particle contrast microCT imaging of normal rat heart. Top-left is the
axial orientation view of the rat heart, and the top-right is the sagittal orientation view of the rat
heart, the bottom-left is the coronal orientation of the rat heart, the bottom-right is the fused 3-D
view of the rat heart.

Figure 3.13 Flow cytometric analysis of levels of rat RBC apoptosis induction and RBC plasma
membrane damage after mock FDG labeling procedure. A：negative control group without any
treatment to RBC, B：FDG RBC test group with all the labeling procedure, C：CaCl2-treat group
which induced much damage to cells. Reprinted from “In vivo positron emission tomographic
blood pool imaging in an immunodeficient mouse model using 18F-fluorodeoxyglucose labeled
human erythrocytes.” by Choi JW, Budzevich M, Wang S, Gage K, Estrella V, Gillies RJ
(2019), PLoS ONE 14(1). Copyright: © 2019 Choi et al. Retrieved:
https://doi.org/10.1371/journal.pone.0211012, Reprinted with permission.
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Figure 3.14 FDG labeling RBC release fraction measurement. Reprinted from “In vivo positron
emission tomographic blood pool imaging in an immunodeficient mouse model using
18F-fluorodeoxyglucose labeled human erythrocytes.” by Choi JW, Budzevich M, Wang S,
Gage K, Estrella V, Gillies RJ (2019), PLoS ONE 14(1). Copyright: © 2019 Choi et al.
Retrieved: https://doi.org/10.1371/journal.pone.0211012, Reprinted with permission.

Table 3.1 Measurement of the tracer activity intensity (BQ/ML) and standardized uptake value
(SUV) in both rest and stress conditions of the heart FDG PET imaging
Heart
Rest
Stress
Difference

Mean
29735.66
32177.48
5186.25

S.E.
8326.20
9511.53
6793.77

SUV
1.00
1.28
0.33

S.E
0.28
0.38
0.31

Table 3.2 Measurement of the tracer activity intensity (BQ/ML) and standardized uptake value
(SUV) in both rest and stress conditions of the brain FDG PET imaging
Brain
Rest
Stress
Difference

Mean
8739.55
20086.95
11368.22

S.E.
3297.56
4040.07
4297.09

SUV
0.17
0.33
0.16

S.E
0.06
0.07
0.07

3.5 Discussion
The work in this chapter demonstrates the feasibility of 18F-FDG labeling RBC as a
novel perfusion tracer for evaluation of total myocardial and cerebral microvascular value under
both rest and pharmacologic stress conditions. As the rat myocardium is 90-95% microvascular
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in volume, we demonstrate through subtraction imaging FDG RBC PET's ability to image the
myocardial microvasculature under both rest and pharmacologic stress conditions. We measured
the myocardial microvascular value using FDG RBC PET imaging and subtraction of stress and
rest conditions images. The total myocardial vascular activity was imaged by FDG RBC PET
images, and the difference between stress and rest conditions was indirectly visualized after
subtraction of stress and rest conditions images. It has adequate image quality, allows for
quantitative evaluation of the total myocardial vasculature under stress and rest conditions.
This work shows that FDG RBCs PET imaging can detect changes in the myocardial and
cerebral vasculature after pharmacological drug-induced vasodilation. We believe that FDG
RBCs PET imaging would also be capable of quantitative myocardial blood flow measurements
on modern clinical PET/CT scanners.
In this work, we find that FDG labeled RBC activity remains largely intravascular in
location during the acquisition time, given possible slow FDG leak from RBC; thus, it should be
theoretically feasible to use one compartmental kinetic modeling for clinical applications. Due to
the small animal PET/CT scanner limitations, the smallest temporal resolution possible with the
Siemens Inveon microPET/CT scanner is one second, which is unfortunately too slow to
accurately use an arterial input function (AIF) myocardium to quantify the absolute myocardial
blood flow (MBF). However, it is not expected to be an issue for clinical application due to the
adequate spatial and temporal resolution of modern PET/CT scanners.
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Chapter 4: Myocardial Microvascular Dysfunction Measurement in Rats with Myocardial
Infarction
4.1 Research Purpose and Experiment Procedure
Heart failure due to acute myocardial infarction, as a significant public health issue, is
one of the leading causes of mortality and morbidity worldwide [46]. Non-invasive imaging in
small animals, like rat and mouse myocardial infarction models, plays an essential role in
pre-clinical research in this area and is used to explore cardiac pathophysiology and infarction
assessment. There are multiple imaging modalities used detection and assessment of myocardial
infarction severity and size, like echocardiography, SPECT, ultrasound, MRI. Magnetic
resonance imaging (MRI) can provide accurate anatomical and functional measurements for
infarction but is limited in the physiologic view of the vasculature disease [47]. Quantification of
myocardial infarction

by using Single-photon emission tomography (SPECT) with

99mTc-sestamibi or high-resolution SPECT is also available; however, there are some technical
limitations such as low spatial resolution [48, 49].
When compared with SPECT, PET, as a thriving technology with high sensitivity, has a
feasibility of quantitative measurements of the cardiovascular system [25]. Like Rubidium-82
[50], 13N-ammonia [51], and 15O water, but all of them have a clinical application due to the
short half-life. 18F-labeled tracers became an attractive way to measure due to their ideal
half-life [52]. FDG has a wide application in clinical in quantitative measurements of
cardiovascular activity. The purpose of this chapter is to see whether RBC containing the
radioactive tracer known as FDG can be used to indirectly look at blood perfusion and
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microvascular dysfunction in infarcted myocardium in a surgical infarction rat heart model using
an imaging technique known as positron emission tomographic (PET) imaging compare to pure
FDG PET imaging and pathology TTC staining analysis. Specifically, the rats undergo surgery to
tie off an artery supplying the rat heart muscle (the "left coronary artery") in order to induce
cellular injury or death in the portion of the heart muscle that is supplied by the left coronary
artery. The rats then undergo PET imaging with the FDG-labeled rat blood cells. It is
hypothesized that PET imaging of FDG-labeled rat red blood cells in the rat heart would show a
relative decrease in the vascularity to the infarcted portion of the rat heart downstream from the
ligated coronary artery when compared to the adjacent uninjured heart muscle.
Rats also undergo PET imaging with regular free FDG and pathology Triphenyl
tetrazolium chloride (TTC) staining analysis. The purpose of imaging these rats with regular
FDG is that regular FDG can also be used to identify the location of heart attacks, as damaged rat
heart muscle has relatively decreased metabolic activity compared to the healthy heart muscle,
and heart muscle uptake of regular FDG is proportional to the degree of metabolic activity. The
Rats undergo surgical ligation of the left coronary artery through an open intercostal approach,
performed at an outside facility by the commercial vendor Envigo, which has extensive
experience in coronary artery ligation of mice and rats.
After the all PET/SPECT imaging has been completed, the rat was sacrificed, and the
heart was removed. The heart was then stained with 2,3,5-Triphenyl tetrazolium chloride (TTC)
(Sigma Aldrich, St. Louis, MO), used by pathologists to identify infarcted myocardium.
Successful imaging of injured heart muscle using FDG-labeled rat red blood cells would confirm
the potential of this technique for characterizing heart attacks in patients with PET imaging. PET
imaging of myocardial infarctions using this technique would represent a significant advance
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over current SPECT-based myocardial perfusion imaging methods done routinely in the clinical
setting, as current clinical 3D-PET scanners have both greater tracer sensitivity (50X) and better
anatomic spatial resolution than typical clinical SPECT cameras.
Rats are imaged 1-6 weeks after surgery, depending on the results of the initial
experiments. Rats are intravenously injected with the FDG-labeled erythrocytes through a tail
vein catheter. Rats undergo microPET/CT imaging after injection of free FDG via tail vein
catheter. Free FDG PET imaging should identify the location of the myocardial infarction as
areas of decreased tracer activity, as infarcted myocardium will have decreased or absent FDG
metabolic uptake. The location of these sites of decreased/absent FDG uptake was compared to
the identified sites of decreased myocardial vascularity seen on the FDG-labeled erythrocyte
PET images.
4.2 Materials and Method
All experiment procedures were approved by the University of South Florida (USF)
Institutional Animal Care and Use Committee (IACUC). All experiments were performed in
accordance to federal regulations and USF IACUC principles and procedures. All the chemicals
obtained from Sigma Aldrich, St. Louis, MO, unless specified. A total of twelve of 4-8 weeks-old
male Sprague Dawley (SD) rats were used, including four health male rats and six myocardial
infarction rats created by using a standardized surgical ligation technique of the proximal rat left
anterior descending artery with ~ 40% ejection fraction (EF) (Envigo, Indianapolis, IN).
4.3 18F-FDG Labeled RBC
The labeling procedure is pretty close to our previous study; much more details, please
find in our previous research[53]. About 500-1000 μl blood was collected in heparin phlebotomy
tube through the rat saphenous vein and stored in a 37 ˚C tissue culture incubator (Sanyo
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Scientific) for 1-2 hours to increase the glucose depletion. After that, rat erythrocytes were
centrifuged 1000 g for 10 minutes, and the remaining plasma and buffer coat residual were
gently removed. The remaining red blood cell pellets were gently resuspended in 4X volume of
filter-sterilized "1X EDTA" solution and centrifuged 1000g for 10 minutes. And the wash buffer
was gently aspirated, and 100 μl 5X EDTA solution and 50 μl deionized water were then added
to the 250 μl washed erythrocytes. Finally, 100 μl (37–74 MBq) USP grade
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F-FDG (Cardinal

Health, Tampa, FL) to a final volume of 500 μl. Samples were incubated in 37 ˚C for 30 minutes,
centrifuged three times, and washed three times with 12 x volume of 1x EDTA/5mM glucose
solution.
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F-FDG labeled RBC PET/CT imaging was performed first, and then the free

18F-FDG PET//CT image was obtained the following week. After image processing, the rat was
sacrificed, and the heart was excised intact, and saline flushed for pathology staining by
2,3,5-Triphenyl tetrazolium chloride (TTC) (Sigma Aldrich, St. Louis, MO) [54]. The rat was
sacrificed, took out the heart, flushed with saline to wash away the remaining blood in the rat
ventricular chamber, and then incubated in -20 ˚C freezer for 30 minutes for easy slicing. The
frozen rat heart was cut into 2 mm transverse-slices in a 3-D printed rat heart mold for uniform
transverse sectioning, incubated in 1% TTC (Sigma Aldrich, St. Louis, MO) buffer solution in 37
˚C bath incubator for 20-30 minutes. The stained myocardial slices were then treated with 10%
formalin for 20-30 minutes [55]. The formalin-treated heart slices were pictured.
4.4 Small Animal PET/CT Imaging
Similar imaging procedure as we previously study, much more details can be found in
the paper by Wang et al [40]. 500-1000 µl of rat blood was drawn through saphenous venous
plexus puncture and collected into the heparinized blood collection tube. The rat was
anesthetized via a nosecone manifold under 2-4% inhalational isoflurane. Insert a tail vein
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micro-catheter into one of the dilated rat tail veins after warm the rat tail. The rat was secured
onto the micro-PET/CT scanner bed under 2-4% inhalational isoflurane anesthesia via a
nose-cone manifold. 250-500 µl of FDG-labeled RBC suspension (the amount of activity range
from 3.7x107-1.01x108 Becquerel) was injected slowly into the rat through the tail vein
microcatheter. Acquire ECG-gated the whole body images of the rat, followed by CT calibration
images. PET/CT image acquisition parameters will depend upon the particular experimental
indications and unique imaging platform set up at a given institution; thus, the following is a
description of the protocol used at our institution. Place electrocardiogram (ECG) leads on two
front limbs and one hind limb of the mouse (ground lead on a rear leg) for ECG gated PET
imaging. The signals detected by these electrodes are recorded during the 20 minute period time
by BioVet® (m2m Imaging) physiological monitoring and heating system.
4.5 PET Image Analysis
The protocol used at our institution is as the following description. Analyze the whole
body PET images of the rat using Inveon Workstation Software (Siemens Medical Inc.,
Knoxville, Tennessee). For 3D PET and 4D PET data sets, manually select multiple volumes of
interest (VOI) based on corresponding CT images for the following organs heart and the brain.
Voxel activities are represented in standardized uptake values (SUV). Plot dynamic activity
curves for VOIs using dynamic 3D PET data set for each animal. The 4D PET data are used for
defining cardiac function. First, segment the heart on CT images based on anatomical features,
then transfer the segmented volume (cardiac PET VOI) for image co-registration. Images are
represented as maximum intensity projection (MIP) reconstructions of the source data. ECG
guided binning of PET MIP images can be performed to obtain pseudo-dynamic images of
mouse cardiac contractility.
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4.6 Myocardial Infarction Size Measurement
The rat heart slices are stained by TTC, the viable tissue stained with red and infarcted
myocardium stained as white. The pictures were analyzed by the “color threshold” mode to
measure infarcted differentiate from viable tissue with ImageJ software (National Institutes of
Health). Left ventricular short axis images were obtained from both FDG images and FDG RBCs
images. Co-register RBC to Free-FDG. Select the same slice from both Free-FDG and RBC
(select a slice where the defect is most visible). After axial segmentation of the left myocardium,
the same slices were chosen from both FDG and RBC PET images for the same rat. Setting
threshold the low signal in the heart (red). The low signal is the heart defected muscle.
Percentage = (area of the defected muscle(red))/( area of all muscle). The infarct size was shown
in percentage.
Segment heart muscle manually and extract activity (i.e., intensities) in the segmented
heart region. And then, divide the extracted intestines into three segments, High, medium, and
low. This is achieved by finding two thresholds using Otsu thresholding algorithm[56]. The low
segment (i.e., region with low activity) is considered as the muscle defect. The percentage was
showed by infarcted percentage= (area of the defected muscle(low))/ (area of all muscle). The
other two regions, high and medium, are considered as normal heart muscles.
4.7 Results
Pathology analysis: the rats have successfully induced infarction after ligating the left
descending artery. As showed in Figure 4.1, the black arrow indicated the ligation site, and the
blue arrow pointed to the infarct area located at the left ventricular wall. As seen in Figure 4.4,
the transverse sliced rat heart TTC staining results from rats 1-6. As results showed, there was
significant scar area and atrophy at the left ventricular wall. The infarcted percentage measured
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by TTC staining ranges from 21.35% to 31.90%. RBC FDG and free FDG PET imaging: after
the axial segmentation of the left myocardium, the same transverse slices were chosen from both
FDG and RBC PET images for the same rat.
The FDG labeled RBC PET images indicated that the decreased area myocardial
vascularity correlated with both the area of decreased metabolic activity in free FDG PET images
and the area of myocardial on tissue staining, as seen in Figure 4.2, A: short axial views of the
left myocardial wall from FDG PET image, the triangle symbols indicate the decreased
metabolic activities in the left ventricular wall. B: short axial views of the left myocardial wall
from RBC PET image; the triangle symbols indicate the decreased vascularity in left ventricular
muscles. The areas were highly correlated between the images of decreased metabolism and
decreased vascularity.
Infarction percentage measurement: the RBC PET images provided a feasible way to
estimate myocardial infarction (MI) size in vivo. After the axial segmentation of the left
myocardium, the same transverse slices were chosen from both FDG and RBC PET images for
the same rat. The same procedure applied to TTC pathology staining, the same transverse slice
was chosen from the same rat; after the TTC staining, the MI size was measured, as in Figures
4.3 & 4.4. Table. 4.1 showed results of MI size measurement based on RBC, FDG PET images,
and TTC pathology staining, separately.
As seen in Figure 4.5, Bland-Altman analysis was performed of MI size assessed by FDG
and TTC, the difference between RBC and FDG measurements, and mean values. The mean
difference between FDG and TTC measurement was 0.91, and the individual measurement
differences are almost distributed in a narrow range around the mean. As seen in Figure 4.6,
Bland-Altman graphic for comparison of MI size assessed by RBC and TTC. The mean

45

difference between TTC hispatology and RBC measurement was 7.875, and the individual
measurement differences are almost distributed in a narrow range around the mean.
We then visually thresholded the activities into “low”, “medium” and “high” ranges.
Some rats showed a “medium” range of activity in the peri-infarct areas of the FDG RBC PET
images with otherwise viable metabolism on FDG images, suggestive of reduced per-infarct
perfusion in “hibernating” (poorly contractile, but otherwise viable) myocardium in these regions.
The decreased perfusion activity in the peri-infarct was correlated with the lower coronary flow
reserve values finding in non-infarct-related arteries as previously reported [57]. Meanwhile,
functional disorders in non-culprit coronary arteries were usually present in acute myocardial
infarction patients [58].
The abnormalities physiology of the peri-infarct myocardial region, like the
cardiovascular event and widespread inflammation, were discussed in the previous study [59].
The "intermediate" threshold signal in the infarction rat hearts should correspond to the
peri-infarct distribution of the coronary arteries in the heart. Also, we observed that these
peri-infarct areas with intermediate FDG RBC signal show relatively "normal" metabolic FDG
uptake, suggesting that this could be "hibernating" myocardium.
4.8 Figures and Tables

Figure 4.1 A simple example for rat heart after ligation of left descending arteries.
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A

B

Figure 4.2 The images demonstrate the shorts axial views of the left myocardium for both FDG
and RBC PET images. A: short axial views of the left myocardial wall from FDG PET image, the
triangle symbols indicate the decreased metabolism activities in the left ventricular wall. B: short
axial views of the left myocardial wall from RBC PET image; also, the triangle symbols indicate
the decreased blood perfusion in left ventricular muscles. They were highly correlated for the
same area decreased metabolism and blood perfusion activities.

Figure 4.3 Same short axial views of Myocardial Infarction rats (number 1-6) cardiac PET
images by FDG and RBC PET imaging, separately. After axial segmentation of the left
myocardial, the same slices were chosen from both FDG and RBC PET images for the same rat.
Automatically threshold the low signal in the heart (red). The low signal is the heart defected
muscle. Percentage = (area of the defected muscle(red))/ (area of all muscle). The infarct size
was shown in percentage. The MI size results were highly correlated between FDG and RBC
PET images.
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Figure 4.4 Transverse sliced rat heart TTC staining results from rat 1-6. As results showed, there
was a significant scar area and variable atrophy at the left ventricular wall.

Table 4.1 Results of MI size measurement based on RBC, FDG PET images, and TTC pathology
staining, separately.
1
2
3
4
5
6
Mean ± S.E.

FDG%
24.38%
29.19%
25.46%
29.26%
27.46%
25.62%
26.93%±0.83%

RBC%
37.19%
29.49
32.85%
29.81%
35.39%
38.64%
33.89%±1.56%

TTC%
25.97%
26.28%
23.58%
21.35%
31.90%
27.04%
26.02%±1.45%
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Figure 4.5 Bland-Altman graphic for comparison of MI size assessed by FDG and TTC, the
difference between RBC and FDG measurements, and mean values.

Figure 4.6 Bland-Altman graphic for comparison of MI size assessed by RBC and TTC, the
difference between RBC and TTC measurement, and their mean values.

4.9 Discussion
Microvascular disease (MVD) refers to vascular diseases that primarily affect the small
arteries, venule, and capillaries in various organs, especially in vital organs like the brain, heart,
and kidney. It is a cause of cardiac ischemia, angina, dementia, stroke, and kidney dysfunction.
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Currently, there is a relative dearth of imaging modalities that readily characterize microvascular
dysfunction, outside of specific indications such as coronary artery catheter-based measurements
such as Index of Microcirculatory Resistance (IMR). Other non-invasive cardiovascular imaging
modalities are used to quantify blood flow and have an advanced understanding of microvascular
dysfunction; nevertheless, most of these suffer from particular limitations, restricting use outside
of specialized academic centers.
This work demonstrates the feasibility of 18F-FDG labeling RBC as a novel perfusion
tracer for evaluation of the total myocardial microvascular volume under both rest and
pharmacologic stress conditions and imaging the microvascular abnormalities associated with
infarcted myocardium. Furthermore, this technique is able to approximate the location of
infarction on the myocardial wall short axial views of 18F-FDG RBC PET imaging. The axial
views of the area of decreased left ventricular myocardial vascularity on FDG RBC PET images
closely matched the deceased myocardial metabolism activity on free FDG PET images as well
as the infarcted myocardium on pathology tissue sampling. FDG RBC PET could be helpful for
diabetic heart disease and other microvascular disease imaging. The data presented here suggests
that FDG RBC PET imaging shows promise as a clinical imaging test for assessing cardiac
perfusion and microvascular dysfunction.
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Chapter 5: Myocardial Microvascular Dysfunction Measurement in Diabetic Rats

5.1 Research Purpose and Study Procedure
Diabetes mellitus (DM) is a long-term multifactorial disease associated with various
vascular complications and became a nationwide health issue and is one of the leading causes of
death in diabetic patients [60]. Diabetes is always associated with both microvascular and
macrovascular complications and is a multifactorial disease associated with a number of
microvascular (cardiomyopathy, retinopathy, neuropathy, and nephropathy) and macrovascular
(ischemic heart disease, cerebrovascular disease, and peripheral vascular diseases) complications
[61-64]. DM can develop many chronic complications, including heart attack and stroke, kidney
failure, leg amputation, vision loss, and nerve damage [62, 65]. Moreover, diabetic mellitus can
also lead to pulmonary vascular disease [66]. Cardiomyopathy of the diabetic is a major cause of
heart failure nationwide [67]. The microvascular abnormalities in diabetic cardiomyopathy are
still unclear. Diabetes-induced endothelial dysfunction is a critical and initiating factor in the
genesis of diabetic vascular complications.
Streptozotocin (STZ) is an antibiotic that produces pancreatic islet β-cell destruction,
leading the animal to experience insulin deficiency [68]. Furthermore, it is widely used in
experiments to induce type 1 diabetes mellitus. In this work, we characterize myocardial
vascularity in a streptozotocin-induced diabetic rat model. Rats were randomly divided into two
groups. One group of 5 rats received 1-2 intravenous tail vein injections 40 mg/kg STZ [69, 70].
The onset and severity of diabetes were confirmed by weekly measurements of peripheral blood
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glucose by needle prick. Moreover, weekly blood drawn for blood glucose concentration
measurement were conducted on fasted rats. The other four rats will serve as normal
age-matched controls. For each rat, 0.5 -1.0 cc's of blood were drawn either via saphenous or
subclavian vein. The red blood cells from this blood sample were labeled with FDG and
re-injected back into the same rat immediately prior to all PET imaging studies.
The mean purpose of this study is to see whether FDG labeled RBC PET imaging
technique could be used to image vascularity in the heart muscle, brain, and other vessels in
diabetic rats. The rats undergo PET imaging with the FDG-labeled rat blood cells. It was
anticipated that PET imaging of FDG-labeled rat red blood cells would show a relative decrease
in the total vascularity of the heart and when compared to the normal age-matched rats without
diabetes.
The PET imaging experiments were conducted in rats from both groups at three month
intervals to 1 year of age in the exact same manner, for the conditions described below:
MicroPET/CT imaging before and after giving the cerebrovascular dilating drug Acetazolamide.
MicroPET/CT imaging before and after giving the myocardial vascular dilating drug
Regadenoson.
The severity of diabetic cardiomyopathy and other diabetic complications depends on the
severity of the streptozotocin-induced pancreatic injury. The progression of diabetic
cardiomyopathy is known to follow steps, with the development of left ventricular (LV) diastolic
dysfunction and ventricular hypertrophy by eight weeks, followed by the development of LV
systolic dysfunction, then decompensated heart failure. FDG RBC PET imaging of the heart of
the first diabetic rats was performed 4-8 weeks after drug treatment to determine which time
interval is optimal for detection of damage to the myocardial microvasculature. Once rats have
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been found to have decreased myocardial microvascular density and impaired myocardial
response to vasodilator challenge with regadenoson, rats were euthanatized. We anticipated that
these findings would be detectable prior to the development of heart failure in most of these rats.
Rats found to have developed decompensated heart failure were euthanatized.
Continuous inhalational anesthesia with isoflurane via nose cone manifold is required to
minimize movements of the rat to allow for good signal acquisition by the PETCT imaging
system during imaging experiments. For imaging data acquisition, rats were induced with
isoflurane in a plastic anesthesia chamber with scavenging. They were then immediately placed
into a rat-suitable holder in the PETCT scanner, outfitted with a nose cone inhalant anesthesia
and scavenging system. The depth of anesthesia is normally assessed by using reflexes
associated with an interdigital pinch.
After a rat had been intravenously injected with either pure FDG or FDG labeled-rat
erythrocytes,

the

rat

was

placed

under

inhalational

anesthesia

into

the

Siemens

microCT/PET/SPECT scanner in the Moffitt SAIL. The tail vein catheter is placed by
appropriate Moffitt vivarium staff using a standardized procedure. After catheter placement,
approximately 200 microliters of a sterile heparin flush solution (10 I.U. USP grade heparin/ml
sterile PBS) are injected into the catheter hub to minimize clotting. Subsequent cell and drug
injection through the catheter were followed by an injection of 200 microliters of heparin flush
solution. The injection of cells was performed slowly over a period of 1-3 minutes. Following
administration of the labeled red blood cells, rats underwent microPET/CT imaging for 15-30
minutes. 25 microgram/kg dose of Regadenoson (100 microliter volume) was then injected
through the tail vein catheter, and the rat underwent additional microPET/CT imaging for 15-30
minutes.
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5.2 Results
The diabetic group rats have pretty similar body weight and glucose level to the normal
controls at baseline, body weight (342.2±32.4 vs. 345.2±34.3, p=0.1516), glucose level
(120.4±5.9 vs. 119.4±7.7, p=0.4162), see Table 5.1. After STZ injection, the diabetic rats’ blood
glucose level typically increased dramatically over 400 mg/dl within 2-3 days, and the
bodyweight slightly dropped down. As shown in Table 5.1, one week after STZ injection, the
diabetic rats’ weight dropped down about 6% (320.8±33.8 vs. 342.2±32.4), and blood glucose
level increased dramatically (473.8±48.2 vs. 120.4±5.9) compared with body weight and glucose
level on the baseline. However, the control group rats’ weight increased about 7% (370.6±32.5 vs.
345.2±34.3), but the blood glucose remained at the same level (125.2±5.9 vs. 119.4±7.7). The
diabetic rats presented hyperglycemia, decreased body weight, and drank more water due to
copious urine when compared with normal age control group rats.
The FDG RBC PET imaging was able to image diabetic rats’ myocardial vascularity
directly. As seen in Figure 5.1, the shorts axial views of the left myocardium for the diabetic rat
and the shorts axial views of the left myocardium for the normal age control rat seen in Figure
5.2. The standardized uptake values (SUV) histograms of the diabetic rat heart and control rat
heart in rest, stress, and difference as showed in Figures 5.3 & 5.4.
The increased percentage of activities was shown: (stress-rest)/rest in diabetic rats and
control group rats, as shown in Tables 5.2 & 5.3, increased percentage between stress and rest
condition myocardium. Compared with control group rats, the stress-induced increase in
myocardial vascularity in diabetic rats is about 50% of the control group (18.82%±2.03% vs.
35.12%±1.91%, p=0.00039), seen in Table 5.4. The impairment in vasodilatory response in the
diabetic group was statistically significant (two-tailed Wilcoxon Rank-Sum test: U = 0 ≤ 2, p <
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0.05, diabetic rat n = 5; normal control n = 5).

However, the diabetic rats’ blood glucose levels

are much higher than the control group, but the mean body weight is about 100 gm less than the
control group.
5.3 Figures and Tables

Figure 5.1 The images demonstrate the shorts axial views of the left myocardium for the diabetic
rat.

Figure 5.2 The images demonstrate the shorts axial views of the left myocardium for the normal
age control rat.
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Figure 5.3 Standardized uptake values (SUV) histograms of the diabetic rat heart.

Figure 5.4 Standardized uptake values (SUV) histograms of the normal rat heart.
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Table 5.1 Body weight and blood glucose of diabetic and control group

Control(n=5
)

Baseline
Diabetes(n=5
)

P-valu
e

1 week
Control(n=5
)

Diabetes(n=5
)

P-value

Body weight
(g)

345.2 ± 34.3

342.2 ± 32.4

0.1516

370.6 ± 32.5

320.8 ± 33.8

0.0018

Blood
glucose(mg/dl
)

119.4 ± 7.7

120.4 ± 5.9

0.4162

125.2 ± 5.9

473.8 ± 48.2

<0.000
1

Table 5.2 Measurement of the tracer activity intensity (BQ/ML) and SUV in both rest and stress
conditions of the diabetic rat heart FDG PET imaging
Diabetic
Rest
Stress
Difference

Bq/ml (mean)
15871.33
20854.55
5779.65

S.D.
5778.18
8383.05
5742.36

SUV (mean)
0.67
0.82
0.19

S.D.
0.24
0.33
0.21

Table 5.3 Measurement of the tracer activity intensity (BQ/ML) and SUV in both rest and stress
conditions of the control rat heart FDG PET imaging

Diabetic
Rest
Stress
Difference

Bq/ml (mean)
37468.94
42433.04
6084.36

S.D.
14167.81
15202.10
6107.70

SUV (mean)
1.27
1.73
0.47

S.D.
0.48
0.62
0.30

Table 5.4 Increased percentage between stress and rest condition myocardium. Body weight and
blood glucose when imaging of diabetic and control group
Weight (g)

Blood glucose (mg/dl)

Control

Increased
percentage
35.12% ± 1.91%

428.3 ± 21.4

80.8 ± 28.4

Diabetes

18.82% ± 2.03%

310.5 ± 36.4

394.0 ± 86.6

P-value

0.00039

<0.0001

<0.0001
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5.4 Discussion
In this work, the rats developed diabetes associated microvascular disease in the
myocardium 5-8 weeks after STZ injection. The aims of this study were to try to image the brain,
heart, and limb vascular damage after STZ induced type 1 diabetes. However, we did not detect
vascular damage from the brain and limbs in the time period examined.
The complications associated with diabetic vascular dysfunction of diabetic are widely
found in various organs like the heart, brain, kidney etc. Unlike atherosclerosis that leads to
injury to the large epicardial vessels of the heart, diabetes affects all vessels throughout the body
and is known for causing significant injury to the microvasculature. The FDG labeled RBC PET
imaging provides a feasible way to examine changes from the myocardial microvascular disease
over time as seen with the impaired vasodilatory response to the vasodilatory drug regadenoson.
This technique would also be amenable to image-based absolute quantification of myocardial
vascularity in the clinical setting. The FDG labeled RBC PET imaging provides an efficient way
for cardiac vascular dysfunction. It has a great potential application for various organ
dysfunction measurements. The complications associated with diabetic vascular dysfunction of
diabetic are widely found in various organs like the heart, brain, kidney, etc.
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Chapter 6: Discussion and Conclusion
FDG, as an FDA approved radiopharmaceutical, has a wide application in vivo glucose
metabolism measurement. It is widely used in oncology PET imaging and regional glucose
metabolism in the human brain. In this study, we provide an easy and direct procedure for
labeling a small volume of RBC with FDG. It is a fairly rapid manual procedure that is relatively
easy to perform and results in a labeling efficiency that is expected to be suitable for clinical PET
imaging. FDG labeled RBC PET imaging is capable of visualizing the entire vasculature of
various organs in rats. As the bulk of the total vascular volume of most organs is microvascular
in size, FDG RBC PET imaging potentially offers a unique advantage over other common
clinical imaging modalities, as it may be able to characterize the underlying microvasculature
and associated disease of an organ of interest. To further demonstrate the abilities of this method,
we show that changes in the rat myocardial vascular response to vasodilatory drugs can be
visualized in normal and diabetic rats, and that response impairment is seen in the diabetic rats
when compared to normal controls. As there are many microvascular pathologies that are not
adequately assessed by current imaging modalities, it is of great interest to our group to advance
the clinical translation of FDG-labeled RBC PET imaging. Evaluation of other microvascular
disease types with this technique in small animal models shall also be pursued in the near future.
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Appendix C: List of Acronyms, Abbreviations, and Symbols
ACD

anticoagulant citrate dextrose

AIF

arterial input function

BQ/ML

becquerel per mililiter

Calcein-AM

acetoxymethl ester of calcein

CMR

cardic magnetic reasonace

CFR

coronary flow reserve

CT

computerize tomography

CTA

computed tomographic angiography

CVD

coronary microvascular dysfunction

DM

diabetes mellitus

ECG

electrocardiogram

FDG

18F-fluorodeoxyglucose

IMR

index of microcirculatory resistance

MBF

myocardial blood flow

mCi

millicuries

ml

mililiter

µl

micorliter

MIP

maximum intensity projection

MRA

magnetic resonance angiography

MVD

microvascular dysfunction
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PET

positron emission tomography

PET/CT

positron emission tomography/computerized tomography

RBC

red blood cells

SPECT

single-photon emission computed tomographic

SUV

standardized uptake values

TTC

triphenyl tetrazolium chloride

VOI

volumes of interest
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